1. Home
  2. OLN vs HRMY Comparison

OLN vs HRMY Comparison

Compare OLN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olin Corporation

OLN

Olin Corporation

HOLD

Current Price

$23.39

Market Cap

2.5B

Sector

Industrials

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.34

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLN
HRMY
Founded
1892
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
OLN
HRMY
Price
$23.39
$35.34
Analyst Decision
Hold
Buy
Analyst Count
13
9
Target Price
$25.23
$44.11
AVG Volume (30 Days)
3.2M
910.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
2.92%
N/A
EPS Growth
N/A
7.97
EPS
N/A
0.55
Revenue
$6,780,800,000.00
$868,453,000.00
Revenue This Year
$2.57
$19.75
Revenue Next Year
$3.51
$12.88
P/E Ratio
N/A
$65.09
Revenue Growth
3.68
21.51
52 Week Low
$18.08
$25.52
52 Week High
$30.46
$40.87

Technical Indicators

Market Signals
Indicator
OLN
HRMY
Relative Strength Index (RSI) 57.30 51.31
Support Level $22.98 $35.05
Resistance Level $24.83 $35.47
Average True Range (ATR) 0.98 1.59
MACD 0.50 -0.20
Stochastic Oscillator 73.56 46.08

Price Performance

Historical Comparison
OLN
HRMY

About OLN Olin Corporation

Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: